ClinicalTrials.gg
Active, not recruitingNCT07043712PULSEUpdated Jan 15, 2026

Effects of Pulse Consumption, Gut Microbiome, and Appetite in Healthy Participants

An interventional study of High pulse consumption in Microbial Colonization and Metabolic Syndrome, sponsored by University of Missouri-Columbia. Active, not recruiting at 1 site in United States. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by University of Missouri-Columbia · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Feb 2023, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 161 studies in Communicable Diseases with a site in United States — 29 open to participants now, 43 under way, none of them phase 3. Communicable Diseases · United States.

Planned enrollment
75th of 115
44 · median 78
Started
2023
with 14 others
No phase
57 of 161
6 open now
Primary completion
2026-12
later than 17 of 40 live
Registered
156th of 161
by date

Among the 161 studies in Communicable Diseases with a site in United States, this one is the 75th largest by planned enrollment of the 115 interventional ones that give a count, is one of 15 that started in 2023, is one of 57 with no phase, reaches primary completion later than 17 of the 40 other live ones, and was the 156th registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

29 of the 161 studies in Communicable Diseases with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 20 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Communicable Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the effects of pulse consumption versus no pulse consumption on the gut microbiome, meal satiety, and short-chain fatty acid metabolomics.

Read the detailed description
  1. Investigate the acute and chronic effects of pulse consumption on the microbiome and plasma SCFA metabolomics in overweight subjects fed a high pulse (n=22) diet versus a no pulse containing diet (n=22).
  2. Furthermore, we will quantitate the rate of production of plasma SCFA, markers of satiety (PYY, GLP-1 and ghrelin), blood lipids, and carbohydrate (CHO) metabolism (glucose levels and oxidation) during a standardized meal to determine the effects of consuming pulses on appetite and satiety after acute and chronic dietary consumption.
  3. We will conduct subjective appetite assessments to investigate appetite control over the short- and long-term.
03

Conditions studied

  • Microbial Colonization
  • Metabolic Syndrome

Keywords

  • overweight
  • satiety
  • SCFA
  • pulses
04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women (premenopausal only)
  • Age 20-55y (we will attempt to start baseline testing at the same time of the menstrual cycle (luteal) for the women
  • ≥25 or ≤40 kg/m2 (most at risk for metabolic abnormalities and will benefit from a pulse intervention-2/3 of Americans are overweight or obese)
  • Weight stable (no fluctuations in body weight of greater than 4 kg in the last 3 months)
  • Willing to consume a research diet
  • Willing to provide blood and fecal samples
  • Sedentary to low active physical activity status (less than 7200 steps per day)
  • Stably treated with statin drugs, anti-hypertensives, and anti-depressants. These are acceptable as long as the drug category does not alter appetite, body weight, or the microbiome (if known)
  • Pre-diabetes acceptable (glucose \<125 mg/dL or \< 6.5%)
  • At least one characteristic of the metabolic syndrome (but not diabetic)

    1. A large waistline: 35 inches or more for women 40 inches or more for men
    2. High triglycerides: 150 mg/dL or higher
    3. Low HDLc level: \<50 mg/dL for women \<40 mg/dL for men
    4. High blood pressure ≥130/85 mmHg
    5. Fasting blood sugar ≥100 mg/dL - Pre-diabetes acceptable (glucose \<125 mg/dL or HbA1c \<6.5%) -

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating
  • (evidence suggests an interplay between the gut microbiome)
  • of \<25 or >40 kg/m2
  • Use of medications that affect the gut microbiome (e.g. antibiotics)
  • Taking medications known to affect appetite (e.g., phentermine) or gastrointestinal function (e.g., metformin)
  • On a special diet or undergoing weight loss, vegetarian, or other restricted dietary patterns
  • Ad libitum intake of fiber above 25g/day (mean intake in the US population is 17g/day) and \< 10g/d
  • History of disease (example colon cancer, , cardiovascular disease, psychiatric disorders, etc.)
  • Use of tobacco products
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    High pulse consumption

    Subjects are provided a high pulse diet for 4-weeks. Tests include: blood biochemistries, a meal tolerance test, body composition measured via DEXA, surveys, fecal sample

    Dietary Supplement: High pulse consumption

  • No intervention
    No pulse consumption

    Subjects are provided a diet that has no pulses for 4-weeks. Tests include: blood biochemistries, a meal tolerance test, body composition measured via DEXA, surveys, fecal sample

Interventions

  • Dietary supplementHigh pulse consumption

    Subjects are provided a high pulse diet for 4 weeks.collection, and anthropometrics measured.

06

What researchers measure

Primary outcomes

  1. gut microbial change

    assessed via 16s rRNA gene sequencing from fecal samples collection

    Time frame: baseline to 4 weeks

  2. Change in appetite hormones

    GLP-1 measurement in plasma samples

    Time frame: baseline to 4 weeks

Secondary outcomes

  1. cardiometabolic risk factors

    total cholesterol,

    Time frame: baseline to 4 weeks

  2. Change in subjective appetite

    Subjective fullness measured via 100 mm visual analogue scale

    Time frame: baseline to 4 weeks

  3. short chain fatty acid metabolomics

    plasma short chain fatty acids

    Time frame: baseline to 4 weeks

  4. Body composition

    Assessed via DEXA during each of two meal test visits

    Time frame: baseline to 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

Of 128 non-industry interventional studies with no phase under Communicable Diseases, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 46 months is above that.

Counting every sponsor, half of 144 studies reached it within 21 months; a quarter within 6 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jun 29, 2025
StartActual
Feb 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07043712
Responsible party
Katherene Anguah (Associate Professor, Nutrition and Exercise Physiology, University of Missouri-Columbia) — Principal investigator
First posted
Jun 29, 2025
Start date
Feb 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion